Evidence map›Paper›PMID 36788983›Full record

ArticleFuture science OA2022

Does post-void residual urine volume affect potential recurrence risk for non-muscle invasive bladder cancer?

Mohammad Talal Al-Zubi, Saddam Al Demour, Samer Fathi Al-Rawashdah, Antonio Carbone, Antonio Luigi Pastore, Mohannad Abuhamad, Saleh Abuorouq, Rami Al-Azab, Morad Bani-Hani, Mohammad Al-Qudah and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Mohammad Talal Al-ZubiDepartment of Surgery, Division of Urology, School of Medicine, Yarmouk University, Irbid, 21110, Jordan.
Saddam Al DemourDepartment of Special Surgery, Division of Urology, School of Medicine, The University of Jordan, Amman, 11972, Jordan.
Samer Fathi Al-RawashdahDepartment of Special Surgery, Urology Unit, School of Medicine, Mutah University, Karak, 61710, Jordan.
Antonio CarboneDepartment of Medico-Surgical Sciences & Biotechnologies, Unit of Urology, Faculty of Pharmacy & Medicine, Sapienza University of Rome, Latina, 04100, Italy.
Antonio Luigi PastoreDepartment of Medico-Surgical Sciences & Biotechnologies, Unit of Urology, Faculty of Pharmacy & Medicine, Sapienza University of Rome, Latina, 04100, Italy.
Mohannad AbuhamadDepartment of Special Surgery, Division of Urology, School of Medicine, The University of Jordan, Amman, 11972, Jordan.
Saleh AbuorouqDepartment of Surgery, Division of Urology, School of Medicine, Yarmouk University, Irbid, 21110, Jordan.
Rami Al-AzabDepartment of Surgery & Urology, School of Medicine, Jordan University of Science & Technology, Irbid, 21110, Jordan.
Morad Bani-HaniDepartment of Special Surgery, Division of Urology, School of Medicine, Hashemite University, Zarqa, 13110, Jordan.
Mohammad Al-QudahFaculty of medicine, University of Jordan, Amman, 11972, Jordan.
Basel ElayanDepartment of Special Surgery, Division of ENT, School of Medicine, The University of Jordan, Amman, 11972, Jordan.
University of Jordan · JOSapienza University of Rome · ITYarmouk University · JOHashemite University · JOJordan University of Science and Technology · JOMutah University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Bladder cancer is the second most common urological malignancy after prostate cancer. Increase in the post-void residual (PVR) volume may result in an increase in the risk of cancer recurrence. Methods: Patient demographic data, tumor stage and grade, PVR volume and 2 years follow-up data for recurrence were obtained and evaluated. Results: One-hundred-and-nineteen patients were subdivided into three groups according to PVR urine volume. The increase of PVR volume was related to short recurrence-free survival (RFS) especially for patients with PVR volume of 60 ml or more. Conclusion: Low PVR volume in patients with non-muscle invasive bladder cancer may play a role in reducing cancer recurrence. However further research is needed in this field.

Indexed as

bladder cancer recurrenceintravesical chemotherapyintravesical immunotherapy (BCG)non-muscle invasive bladder cancers (NMIBCs)post-voiding residual urine volume (PVR)trans urethral resection of bladder tumor (TURBT)

Identifiers

PMID36788983
PMCPMC9912276
OpenAlexW4317809223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.